Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL813232 | 0.83 | GABRA1 (0.38) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL813829 | 0.83 | GABRA1 (0.38) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL813263 | 0.79 | GABRA1 (0.38) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL813389 | 0.79 | GABRA1 (0.34) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL813514 | 0.79 | GABRA1 (0.34) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL814126 | 0.79 | GABRA1 (0.34) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL816114 | 0.79 | GABRA1 (0.34) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL814658 | 0.78 | SCN4A (0.36) | LMNA | |
| SCHEMBL5167903 | 0.78 | GABRA1 (0.43) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 | |
| SCHEMBL814211 | 0.76 | GABRA1 (0.38) | GABRA1GABRB2LMNASMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | claimed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | claimed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | claimed |
| US-8058372-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20080319147-A1 | Catalyst Composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2008-12-25 | — | — | US | disclosed |
| US-7371803-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20070066776-A1 | Catalyst composition II | SOLAN GREGORY A | 2007-03-22 | — | — | US | disclosed |
| US-7189791-B2 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-20040266961-A1 | Catalyst composition II | EXXONMOBIL CHEMICAL PATENTS INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266961-A1 | Catalyst composition II | MLX, CBX2, BMX | GABRA1 4178/4885GABRB2 3205/4885LMNA 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.